title: Toxic and Endocrine Myopathies.
abstract: OBJECTIVE
  This article discusses the clinical features, pathophysiology, and management of toxic and endocrine myopathies.
  
  
  RESULTS
  Early detection and expeditious correction of metabolic disturbances in endocrinopathies such as Cushing syndrome, thyroid and parathyroid diseases, and acromegaly can minimize and prevent neurologic complications including myopathy. Recently proposed mechanisms of injury in patients with critical illness myopathy include inhibition of protein synthesis, mitochondrial dysfunction, disruption of the ubiquitin-proteasome system, oxidative stress, and disruption of intramuscular calcium homeostasis, which can cause a myosin-loss myopathy. Mechanisms underlying toxic myopathies include myosin loss; damage to cellular structures, including myofibrils and organelles such as lysosomes and mitochondria; inflammation; and necrosis. Presentations range anywhere from acute, painful, and necrotic myopathies, as can occur in statin myopathy, to more insidious presentations such as steroid myopathy.
  
  
  CONCLUSIONS
  Endocrinopathies known to cause myopathy include thyroid and parathyroid diseases, disorders of the adrenal axis such as Cushing syndrome, and acromegaly. Patients in the intensive care unit are at risk for developing critical illness myopathy, also known as myosin-loss myopathy, which should be considered if intensive care unit acquired weakness develops. The most common toxic agents associated with myopathy include statins and other lipid-lowering medications, corticosteroids, colchicine, amiodarone, hydroxychloroquine, and chloroquine.
authors.forename: Hans D
authors.initials: HD
authors.lastname: Katzberg
authors.forename: Charles D
authors.initials: CD
authors.lastname: Kassardjian
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D004700:Endocrine System Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000628:therapy; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D007037:Hypothyroidism / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000628:therapy; D007362:Intensive Care Units / Q000639:trends; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000628:therapy; D011115:Polyneuropathies / Q000000981:diagnostic imaging* / Q000628:therapy
chemical_list: D000305:Adrenal Cortex Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors